Ivermectin

COVID-19

Sylvester Researcher Finds FDA-Approved Antiviral Drug Can Be Delivered Via Nanoparticle for COVID-19

A Sylvester Comprehensive Cancer Center researcher at the University of Miami Miller School of Medicine has found that an orally administered nanoparticle can deliver the FDA-approved drug Ivermectin to suppress the COVID-19 virus. “Our…

Dec. 02 2020 | Share

University of Miami Leads a Pilot Program to Track Variants of COVID-19

Researchers Recruiting for Wearable Device Study to Help Detect COVID-19 Upon Infection

Dr. Anthony Fauci Shares Insights about COVID-19’s Lessons and Challenges

Miller School Professors Develop Model To Correct COVID-19 Sampling Bias

Programs Benefiting Sylvester Cancer Survivors Adapt and Thrive Throughout Pandemic

Dr. Joslyn Gober is New Medical Director of Pediatric Rehabilitation

Dr. Rivka C. Stone Joins UHealth Dermatology

UHealth Dermatology Welcomes Dr. Fabrizio Galimberti

Significant New Findings about Breast and Ovarian Cancer in Patients from the Caribbean

Sylvester Researcher Works to Eliminate the ‘Blind Spot’ of Racism

The Healing Power of Tattoos: Hope vs. Cancer Lifts Spirits and Raises Critical Funds for Pediatric Cancer Research

Study of Mitochondrial Protein Synthesis by Miller School Team Earns Cover of Journal Science

The Healing Power of Tattoos: Hope vs. Cancer Lifts Spirits and Raises Critical Funds for Pediatric Cancer Research

Dr. Gaetano Ciancio Wins Prestigious National Award for Transplant Surgery Mentorship

Miller School Awarded National Grant to Address Health Disparities During Pandemic

Resident Feeds Off-duty Passion with Good Samaritan Meals

Ivermectin

Sylvester Researcher Finds FDA-Approved Antiviral Drug Can Be Delivered Via Nanoparticle for COVID-19